NurExone Biologic Inc. announced significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality. These achievements include an amplified immuno-modulatory response which means helping the immune system to respond to injury and reducing the inflammation activity and in parallel, significantly improved cellular uptake, allowing NurExone's EVs better cell penetration, holding great promise for the Company's future EVs-based therapies.

Through production methodologies, NurExone aims to unlock the full potential of EVs as powerful therapeutic tools. The Company's exclusive and unique 3D-Flow process involves culturing EVs on a 3D "scaffold" and subjecting the stem cells to flow-induced shear stress stimulation during production. This innovative technique, which was developed in the lab of Professor Shulamit Levenberg at the Technion (Haifa) and exclusively licensed to the Company, has already demonstrated increased yield in production1.

The current study, performed by the Company, assessed functional properties of EVs, cultured using different production techniques. The EVs derived from Human Bone Marrow Mesenchymal Stem Cells (hBM-MSC) and produced via 3D-Flow demonstrated a superior ability to decrease the inflammatory response of cells compared with a standard control and other production techniques, suggesting effectiveness in decreasing inflammation. Furthermore, the groundbreaking 3D-Flow production has led to EVs with significantly improved cellular uptake, compared with EVs produced by other production techniques.

This is critical to ensure targeted delivery of therapeutic cargo to specific cell types, maximizing the potential of EVs as drug delivery vehicles. EVs have gained considerable attention in recent years due to their potential as natural therapeutic carriers. Demonstrating modulation of immune response, and superior uptake of EVs in the target cells will assist in moving from the laboratory to the clinical setting.

NurExone is committed to further exploring the potency and therapeutic benefits of EVs produced through the 3D-Flow process using rigorous preclinical and clinical studies. The Company's wholly-owned subsidiary, NurExone Biologic Ltd. has obtained an exclusive worldwide license from the Technion to develop and commercialize the production process for use for additional indications. Based on the study results, the Company is pursuing a patent application in the United States and other key markets under the Patent Cooperation Treaty (PCT).

Once the production process is finalized, NurExone intends to monetize this technology by licensing it to other companies within the global biopharmaceutical industry in addition to implementing it within its proprietary drug platform.